San Francisco
San Francisco, California, 94143, United States
NCT Number: NCT00086385
The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.
Looking for future studies?
Notify Me50 year and older
All sexes
Interventional
Phase 3
San Francisco, California, 94143, United States
The overall goals of this line of research were to prevent relapse to cigarette smoking, and to understand the processes related to smoking and relapse. The specific aims of the current study were to test a series of hypotheses about the efficacy and cost-effectiveness of long-term, tailored interventions in chronic, older smokers and the interaction of these interventions with gender and depression. Participants were 50 years or older and smoker 10 or more cigarettes per day. Baseline assessments includes measures of smoking behavior, nicotine dependence, depression diagnosis, demographics and life circumstances and measures of anger, depression and mood disturbance, stress, social support, health status, motivation for changed and drug and alcohol use.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
smokers of at least 10 cigarettes per day
Inclusion criteria
MULTIPLE
Exclusion criteria
MULTIPLE
Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
Other names: Nicorette, Zyban
Time frame: Two years
Primary outcome variable was 7-day point prevalence cigarette abstinence verified biochemically at week 104
University of California, San Francisco
Other
Maintaining Nonsmoking: Older Smokers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737288
Behavior, Chemically-Induced Disorders
Izmir, Turkey (Türkiye)
View Trial DetailsNCT03950427
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial DetailsNCT03922360
Behavior, Chemically-Induced Disorders
Burlington, Vermont, United States
View Trial DetailsNCT05729243
Alcohol Use Disorder, Alcohol-Related Disorders
Toronto, Ontario, Canada
View Trial Details